Novartis nixes 6 ph. 1 assets, adds 2 new cancer candidates
Novartis has nixed six early-stage pipeline programs, swapping in two new phase 1 cancer candidates as replacements. The…
Nurix, Roche ink bexobrutideg BTK deal up to $2.3B
Nurix Therapeutics (Nasdaq: NRIX) announced a global collaboration with Roche to co-develop and…
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Pluvicto®PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancer Kisqali®…
Managing Quality of Life with CML
Understanding chronic myeloid leukemia Chronic myeloid leukaemia (CML) is a type of cancer that develops in the blood-forming…
Merck’s $6.7B Terns Acquisition Positions It to Challenge a Blockbuster Novartis Cancer Drug
Merck is picking up a big new piece for its cancer drug pipeline with a $6.7 billion deal…
25 Year Anniversary of Innovation in Treating CML
Twenty-Five Years of Community: How Living With CML Has Changed—and Brought Patients Together Discussion notes from the Second…
Roche to Present 46 Abstracts, 12 Orals at ASH Meeting
Roche (OTCQX: RHHBY) will present 46 abstracts, including 12 oral presentations, at ASH…
Roche Receives Conditional Authorisation for Lunsumio SC
Roche (OTCQX: RHHBY) announced the European Commission granted conditional marketing authorisation for Lunsumio…